We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

17 hedge funds and large institutions have $9.16M invested in Kiora Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,366% more capital invested

Capital invested by funds: $625K → $9.16M (+$8.54M)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 16 → 17 (+1)

0.01% more ownership

Funds ownership: 0% → 0.01% (+0.01%)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$8.16M
2
EIM
Essex Investment Management
Massachusetts
+$39.5K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$19.7K
4
RJFSA
Raymond James Financial Services Advisors
Florida
+$8.46K
5
UBS Group
UBS Group
Switzerland
+$8.46K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$14.1K
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$11K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$6K
4
TSS
Two Sigma Securities
New York
-$5K
5
CS
Credit Suisse
Switzerland
-$2.82K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$8.9M +$8.16M +2,891 +1,308%
Vanguard Group
2
Vanguard Group
Pennsylvania
$61K +$19.7K +7 +50%
EIM
3
Essex Investment Management
Massachusetts
$39K +$39.5K +14 New
Barclays
4
Barclays
United Kingdom
$35K +$5.64K +2 +20%
US Bancorp
5
US Bancorp
Minnesota
$22K – – –
Citadel Advisors
6
Citadel Advisors
Florida
$14K -$14.1K -5 -50%
IA
7
IFP Advisors
Florida
$14K +$2.82K +1 +25%
CS
8
Credit Suisse
Switzerland
$12K -$2.82K -1 -20%
WS
9
Wedbush Securities
California
$11K – – –
Northern Trust
10
Northern Trust
Illinois
$8K – – –
RJFSA
11
Raymond James Financial Services Advisors
Florida
$8K +$8.46K +3 New
UBS Group
12
UBS Group
Switzerland
$8K +$8.46K +3 New
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$7K – – –
Invesco
14
Invesco
Georgia
$6K +$5.64K +2 New
LTFS
15
Ladenburg Thalmann Financial Services
Florida
$4K – – –
Morgan Stanley
16
Morgan Stanley
New York
$3K – – –
VIA
17
Vantage Investment Advisors
Pennsylvania
$3K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
– -$11K -5 Closed
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
– -$6K -3 Closed
TSS
20
Two Sigma Securities
New York
– -$5K -2 Closed
HFP
21
Holistic Financial Partners
Indiana
– -$1K – –

KPRX Hedge Fund Activity: Q2 2018 in Review

17 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2018, worth a combined $9.16M — up 1,366% from $625K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new KPRX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, adding an estimated $8.16M. The largest seller was Citadel Advisors, cutting an estimated $14.1K.

  • 17 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2018, up from 16 in Q1 2018.
  • Funds reported $9.16M of Kiora Pharmaceuticals stock for Q2 2018, up 1,366% quarter-over-quarter.
  • 4 funds opened new Kiora Pharmaceuticals positions in Q2 2018 and 3 closed out, a net change of +1 holder.
  • The largest Kiora Pharmaceuticals buyer in Q2 2018 was Armistice Capital, an estimated $8.16M added.
  • The largest Kiora Pharmaceuticals seller in Q2 2018 was Citadel Advisors, an estimated $14.1K sold.

Based on aggregated 13F filings for Q2 2018.